U.S. Registry Data Confirm Liver Risk With Avacopan for Vasculitis Treatment
Source Summary
A new study using U.S. registry data has confirmed liver risk associated with avacopan (Tavneos), a drug approved in 2021 by the FDA to treat anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. The FDA has requested that manufacturer Amgen withdraw the drug from the market.
Why it matters
The confirmed liver risk strengthens the FDA's position to remove a drug from the market that was approved for a serious autoimmune condition, affecting treatment options for patients with ANCA-associated vasculitis.
